Bioxcel Therapeutics, INC. (BTAI) — 8-K Filings

All 8-K filings from Bioxcel Therapeutics, INC.. Browse 49 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (49)

8-K Filing — Apr 1, 2026
BioXcel Therapeutics Files 8-K on Financials — Mar 27, 2026 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on March 27, 2026, reporting on its financial condition and results of operations. The filing includes financial stateme
BioXcel Therapeutics Files 8-K on Shareholder Vote Matters — Dec 15, 2025 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on December 15, 2025, reporting on a submission of matters to a vote of security holders that occurred on December 12, 2
8-K Filing — Nov 10, 2025
BioXcel Therapeutics Files Routine 8-K — Oct 30, 2025 Risk: low
On October 30, 2025, BioXcel Therapeutics, Inc. filed an 8-K report. The filing indicates no specific material events or changes requiring immediate disclosure
BioXcel Therapeutics Files 8-K — Oct 14, 2025 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting an 'Other Event'. The filing does not contain specific details about the event itself, bu
BioXcel Therapeutics Files 8-K — Sep 15, 2025 Risk: medium
BioXcel Therapeutics, Inc. filed an 8-K on September 15, 2025, reporting on events that occurred on the same date. The filing is primarily a Regulation FD Discl
BioXcel Therapeutics Files 8-K: Other Events — Sep 10, 2025 Risk: medium
On September 10, 2025, BioXcel Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but the specific details of this event are n
BioXcel Therapeutics Files 8-K — Aug 27, 2025 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on August 27, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the even
BioXcel Therapeutics to be Acquired by Jabbok Affiliate — Aug 18, 2025 Risk: medium
BioXcel Therapeutics, Inc. announced on August 18, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Jabbok, LLC. The tran
BioXcel Therapeutics to be Acquired by Kindred Biosciences Affiliate — Aug 15, 2025 Risk: medium
BioXcel Therapeutics, Inc. announced on August 14, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Kindred Biosciences,
BioXcel Therapeutics Files 8-K — Aug 12, 2025 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and
BioXcel Therapeutics Files 8-K — Aug 11, 2025 Risk: low
On August 11, 2025, BioXcel Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material e
BioXcel Therapeutics Files 8-K — Aug 6, 2025 Risk: medium
BioXcel Therapeutics, Inc. filed an 8-K on August 6, 2025, reporting an "Other Event." The filing does not contain specific details about the event, its nature,
BioXcel Therapeutics Files 8-K — Aug 1, 2025 Risk: medium
BioXcel Therapeutics, Inc. filed an 8-K on August 1, 2025, reporting an 'Other Event'. The filing does not contain specific details about the event, dollar amou
BioXcel Therapeutics Files 8-K — Jul 21, 2025 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on July 21, 2025, reporting other events. The company, incorporated in Delaware with its principal executive offices in
BioXcel Therapeutics Files 8-K: Other Events — Jul 15, 2025 Risk: medium
On July 15, 2025, BioXcel Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but the specific details of this event are not el
BioXcel Therapeutics Files 8-K: Other Events — May 27, 2025 Risk: medium
BioXcel Therapeutics, Inc. filed an 8-K on May 27, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events
BioXcel Therapeutics Files 8-K on Financials — May 12, 2025 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on May 12, 2025, to report on its results of operations and financial condition. The filing includes financial statement
BioXcel Therapeutics Enters Material Definitive Agreement — Apr 3, 2025 Risk: medium
BioXcel Therapeutics, Inc. announced on April 3, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its
BioXcel Therapeutics Files 8-K on Financials — Mar 27, 2025 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on March 27, 2025, reporting on its results of operations and financial condition. The filing includes financial stateme
BioXcel Therapeutics Files 8-K for Other Events — Mar 21, 2025 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on March 21, 2025, reporting an event that occurred on March 20, 2025. The filing pertains to 'Other Events' and does no
BioXcel Therapeutics Enters Material Definitive Agreement — Mar 4, 2025 Risk: medium
On March 3, 2025, BioXcel Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement or a
BioXcel Therapeutics Files 8-K — Mar 3, 2025 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on March 3, 2025, reporting an event on February 28, 2025. The filing is categorized under 'Other Events' and does not s
BioXcel Therapeutics Files 8-K with Corporate Updates — Feb 6, 2025 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on February 6, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements with exhib
BioXcel Therapeutics Files 8-K on Shareholder Votes — Jan 29, 2025 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on January 29, 2025, reporting on matters submitted to a vote of security holders as of January 28, 2025. The filing det
BioXcel Therapeutics Announces Board and Executive Changes — Jan 16, 2025 Risk: medium
BioXcel Therapeutics, Inc. announced on January 15, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depa
BioXcel Therapeutics Announces Board and Executive Changes — Jan 8, 2025 Risk: medium
BioXcel Therapeutics, Inc. announced on January 7, 2025, a change in its board of directors and executive compensation arrangements. The filing details the depa
BioXcel Therapeutics Enters Material Definitive Agreement — Nov 25, 2024 Risk: medium
BioXcel Therapeutics, Inc. announced on November 22, 2024, that it entered into a material definitive agreement. The filing does not provide specific details on
BioXcel Therapeutics Files 8-K: Agreements, Equity Sales, Officer Changes — Nov 21, 2024 Risk: medium
BioXcel Therapeutics, Inc. filed an 8-K on November 21, 2024, reporting on several key events. These include entering into a material definitive agreement, unre
BioXcel Therapeutics Files 8-K for Financials — Nov 14, 2024 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on November 14, 2024, to report on its results of operations and financial condition, as well as to file financial state
BioXcel Therapeutics Appoints New CMO, Director — Oct 9, 2024 Risk: medium
BioXcel Therapeutics, Inc. announced on October 3, 2024, the appointment of Dr. Robert J. Henninger as Chief Medical Officer and the election of Dr. William D.
BioXcel Therapeutics Faces Delisting Notice — Sep 20, 2024 Risk: high
BioXcel Therapeutics, Inc. filed an 8-K on September 20, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, inco
BioXcel Therapeutics: CMO Departs, New Directors Appointed — Sep 19, 2024 Risk: medium
BioXcel Therapeutics, Inc. announced on September 17, 2024, the departure of its Chief Medical Officer, Dr. Robert L. Neville. The company also elected two new
BioXcel Therapeutics to be Acquired by Kindred Biosciences Affiliate — Sep 9, 2024 Risk: medium
BioXcel Therapeutics, Inc. announced on September 5, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Kindred Biosciences
BioXcel Therapeutics to be Acquired for $1.1 Billion — Sep 5, 2024 Risk: medium
BioXcel Therapeutics, Inc. announced on September 5, 2024, that it has entered into a definitive agreement to be acquired by J.P. Morgan Acquisition Corp. for a
BioXcel Therapeutics Files 8-K on Financials — Aug 6, 2024 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition. The filing includes financial stateme
BioXcel Therapeutics Enters Material Definitive Agreement — Jul 17, 2024 Risk: medium
BioXcel Therapeutics, Inc. announced on July 11, 2024, that it entered into a material definitive agreement. The company, incorporated in Delaware with its prin
BioXcel Therapeutics Files 8-K — Jul 16, 2024 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on July 16, 2024, to report on its results of operations and financial condition, as well as to file financial statement
BioXcel Sells Neuroscience Drug Candidate to Sun Pharma for $10M — Jun 25, 2024 Risk: medium
BioXcel Therapeutics, Inc. announced on June 25, 2024, that it has entered into a definitive agreement to sell its neuroscience drug candidate, BXCL-501, to a s
BioXcel Therapeutics Files 8-K on Corporate Changes — Jun 12, 2024 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on June 12, 2024, reporting on events that occurred on June 10, 2024. The filing indicates changes to the company's arti
BioXcel Therapeutics Files 8-K on Financials — May 9, 2024 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial statements
BioXcel Therapeutics Files 8-K — Apr 22, 2024 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on April 22, 2024, to report on other events and financial statements. The filing does not contain specific details abou
BioXcel Therapeutics to be Acquired for $1.00/Share — Apr 10, 2024 Risk: medium
BioXcel Therapeutics, Inc. announced on April 10, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Kindred Health Holding
BioXcel Therapeutics Files 8-K — Mar 25, 2024 Risk: low
On March 25, 2024, BioXcel Therapeutics, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial sta
BioXcel Therapeutics Files 8-K on Financials — Mar 12, 2024 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on March 12, 2024, reporting on its results of operations and financial condition. The filing includes financial stateme
BioXcel Therapeutics Files 8-K for Regulation FD Disclosure — Feb 14, 2024 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K with the SEC on February 14, 2024, reporting an event that occurred on the same date. The filing indicates disclosure un
BioXcel Therapeutics Files 8-K on Material Definitive Agreement — Feb 12, 2024 Risk: medium
BioXcel Therapeutics, Inc. filed an 8-K on February 12, 2024, to report an "Entry into a Material Definitive Agreement." This filing indicates a significant new
BioXcel Therapeutics Files 8-K for Other Events on Feb 7, 2024 — Feb 8, 2024 Risk: low
BioXcel Therapeutics, Inc. filed an 8-K on February 7, 2024, under the 'Other Events' category. This filing indicates that the company is making a routine discl

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX